Smart Capital Traders
  • Politics
  • Investing
  • Latest News
  • Stocks

Smart Capital Traders

  • Politics
  • Investing
  • Latest News
  • Stocks
Politics

Republican senator claims RFK Jr. mRNA vaccine decision undermines Trump agenda

by admin August 8, 2025
August 8, 2025
Republican senator claims RFK Jr. mRNA vaccine decision undermines Trump agenda

Sen. Bill Cassidy, R-La., has condemned the Department of Health and Human Services’ move to shift funding away from mRNA vaccine development, claiming it undermines President Donald Trump’s agenda to make the nation healthy again.

‘We reviewed the science, listened to the experts, and acted,’ Department of Health and Human Services Sec. Robert F. Kennedy Jr. said, according to an HHS press release.

‘BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We’re shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.’

Cassidy registered his objection to the move.

‘It is unfortunate that the Secretary just canceled a half a billion worth of work, wasting the money which is already invested. He has also conceded to China an important technology needed to combat cancer and infectious disease. President Trump wants to Make America Healthy Again and Make America Great Again. This works against both of President Trump’s goals,’ the lawmaker said in a post on X. 

The HHS stated, ‘While some final-stage contracts (e.g., Arcturus and Amplitude) will be allowed to run their course to preserve prior taxpayer investment, no new mRNA-based projects will be initiated. HHS has also instructed its partner, Global Health Investment Corporation (GHIC), which manages BARDA Ventures, to cease all mRNA-based equity investments. In total, this affects 22 projects worth nearly $500 million. Other uses of mRNA technology within the department are not impacted by this announcement.’

Fox News Digital reached out to Cassidy’s office to request comment from the senator on Thursday, but did not receive a response by the time of publication.

Cassidy, who has served in the upper chamber since 2015, is aiming to get re-elected in 2026, though the incumbent faces competition from other Republicans who have also launched bids for the Senate seat.

In February 2021, Cassidy voted to convict Trump after the House impeachment in the wake of the January 6 episode at the U.S. Capitol. That Senate vote, which occurred after Trump had already left office, ultimately fell short of the threshold necessary to convict.

This post appeared first on FOX NEWS

previous post
Who is Anita Dunn? The Biden confidante who clashed with Hunter grilled in House autopen probe
next post
S&P 500 Breaking Out Again: What This Means for Your Portfolio

related articles

Here’s what happened during Trump’s 10th week in...

March 29, 2025

Trump earns bipartisan praise for decisive action against...

June 22, 2025

Trump-backed candidate Asfura wins Honduras presidential election

December 25, 2025

Woman who filed a complaint against Epstein to...

December 21, 2025

Eric Adams says Biden DOJ used ‘lawfare’ against...

December 30, 2025

Crunch time: Harris to team up with Barack...

October 18, 2024

Trump cuts China tariff after Xi signals tougher...

October 30, 2025

Scathing report claims nation’s oldest labor union ‘betrayed’...

March 30, 2026

White House takes interest in proposed Russian sanctions...

June 13, 2025

CLAY TRAVIS: The GOP’s 2026 challenge — holding...

November 7, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Most Popular

    • 1

      Environmental Approval for Boland Infield Studies & Update on Scaled Column ISR Test

      September 19, 2025
    • 2

      Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions

      October 19, 2024
    • 3

      Retraction of Forecast Financial Information Plus Announcement on New Metallurgical Testwork Results

      October 15, 2024
    • 4

      As North Korea, Iran and China support Russia’s war, is a ‘new axis’ emerging?

      October 25, 2024
    • 5

      Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

      October 31, 2024

    Categories

    • Investing (3,716)
    • Latest News (2,300)
    • Politics (4,600)
    • Stocks (1,442)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smartcapitaltraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartcapitaltraders.com | All Rights Reserved